Patricia K. Coyle, MD
Professor and Acting Chair
Department of Neurology
SUNY Stony Brook
Stony Brook, NY
Clyde E. Markowitz, MD
Associate Professor of Neurology
Director of the MS Center
University of Pennsylvania
AMA PRA Category 1 Credits™
1.2 contact hours for nursing credit Medium
THIS ACTIVITY WAS ORIGINALLY PRESENTED AS A LIVE AUDIOCONFERENCE SERIES BEGINNING DECEMBER 21, 2010 THROUGH FEBRUARY 22, 2011. IF YOU RECEIVED CREDIT FOR PARTICIPATING IN THE AUDIOCONFERENCE, YOU ARE NOT ELIGIBLE TO RECEIVE CREDIT FOR THIS ONLINE ACTIVITY.
An estimated 350,000 to 500,000 people in the United States are currently diagnosed with multiple sclerosis (MS), a chronic, neurologic disorder with potential for substantial negative impact on quality of life. A wide variety of neurological symptoms can occur with MS, including tingling and numbness, loss of balance, weakness in one or more limbs, and vision problems. Treatment is focused on returning function after an attack, preventing new attacks, and preventing disability.
Neurologists and other members of the treatment team who care for patients with MS play an important role in providing optimal treatment to improve patient outcomes. However, the heterogeneity of the pathogenesis of MS and wide variation in the clinical course for each patient make management of MS challenging for clinicians. Neurologists have an opportunity to improve the treatment of MS by expanding their ability to individualize treatment decisions for each patient at each stage of MS. The goal of this continuing education activity is to provide an update to physicians and other health care providers on the optimal treatment approaches for MS with a focus on tailoring treatment for each individual patient.
o Overview, Front Matter, Pre-Test: 15 minutes
o Slides & Audio: 40 minutes
o Q &A, Evaluation, Post Test: 20 minutes Program Developer/Facilitator
. Target Audience
The educational design of this activity addresses the needs of neurologists, neurological nurses, and other health care providers involved or interested in the treatment of patients with multiple sclerosis.
In order to obtain credit, participants must complete the activity in full as well as the Post-test and Evaluation. Learning Objectives
Upon completion of this educational activity, the participant should be able to:
Explain when a change in MS treatment is warranted due to suboptimal response to current MS treatment.
Describe the role of clinical evaluation and imaging studies when monitoring individual response to MS therapy.
Recognize and manage adverse effects of disease-modifying therapy for patients with MS.
Global Education Group (Global) requires instructors, planners, managers and other individuals and their spouse/life partner who are in a position to control the content of this activity to disclose any real or apparent conflict of interest they may have as related to the content of this activity. All identified conflicts of interest are thoroughly vetted by Global for fair balance, scientific objectivity of studies mentioned in the materials or used as the basis for content, and appropriateness of patient care recommendations.
The faculty reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME activity:
Patricia K. Coyle, MD: Consultant/Independent Contractor: Acorda, Biogen Idec, EMD Serono, Novartis, Teva Neurosciences; Honoraria: Bayer, Pfizer
Clyde E. Markowitz, MD: Consultant/Independent Contractor: Bayer, Biogen Idec, EMD Serono, Novartis, Teva, Wyeth/Pfizer; Grant/Research Support (through university): Bayer, Biogen Idec, EMD Serono, Novartis, Teva; Honoraria: Bayer, Biogen Idec, EMD Serono, Novartis, Teva
The planners and managers reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME activity:
Jackie Dawson, MSN: Nothing to disclose
Amanda Glazar, PhD: Nothing to disclose
Sara Thier, MPH: Nothing to disclose
Elizabeth Paczolt, MD: Other/Royalty: Gilead Sciences Inc., Novartis, Merck, Ortho-McNeil-Janssen
David Heckard: Nothing to disclose
Disclosure of Unlabeled Use
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. Global Education Group (Global) and Medical Communications Media, Inc. do not recommend the use of any agent outside of the labeled indications.
The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of any organization associated with this activity. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
Physician Continuing Medical Education
This activity has been planned and implemented in accordance with the Essential Areas and Policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint sponsorship of Global Education Group (Global) and Medical Communications Media, Inc. Global is accredited by the ACCME to provide continuing medical education for physicians.
Global Education Group designates this enduring material for a maximum of 1.25 AMA PRA Category 1 Credits™. Physicians should only claim credit commensurate with the extent of their participation in the activity.
Nursing Continuing Education
This educational activity for 1.2 contact hours is provided by Global Education Group.
Global Education Group is an approved provider of continuing nursing education by the Colorado Nurses Association, an accredited approver by the American Nurses Credentialing Center’s Commission on Accreditation.
Nurses are only elgibile for full credit for this activity.
For information about the accreditation of this program, please contact Global at 303-395-1782 or firstname.lastname@example.org.
This activity is jointly sponsored by Global Education Group and Medical Communications Media, Inc.
Commercial Support Statements
This activity is supported by an educational grant from Biogen Idec and Elan Pharmaceuticals, Inc.